Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05326932

Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial

Led by The George Institute for Global Health, China · Updated on 2026-03-06

382

Participants Needed

1

Research Sites

282 weeks

Total Duration

On this page

Sponsors

T

The George Institute for Global Health, China

Lead Sponsor

C

Changhai Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

A multi-center, prospective, randomized, open-label, adaptive group sequential designed, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS

CONDITIONS

Official Title

Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Stroke occurred 24 to 72 hours before enrollment
  • Clinical diagnosis of acute ischemic stroke due to large vessel occlusion in the anterior brain circulation
  • NIH Stroke Scale score of 6 or higher at randomization
  • Evidence of viable brain tissue on CT or MRI perfusion scans with infarct core volume less than 50 mL, mismatch ratio 1.8 or higher, and mismatch volume 15 mL or higher
  • Written informed consent obtained from patient or proxy
Not Eligible

You will not qualify if you...

  • Unlikely to benefit from the trial due to conditions like advanced dementia, major pre-stroke disability, or high chance of early death
  • Major co-existing diseases that affect follow-up or outcomes (e.g., cancer, severe heart or kidney failure)
  • Pregnancy
  • Unable to undergo CT or MRI perfusion imaging
  • Known allergy to iodine, heparin, anesthesia, or contraindication to endovascular treatment
  • Seizures at stroke onset or before randomization preventing accurate stroke severity assessment
  • Extremely low or high blood glucose levels at baseline
  • Low platelet count below 50,000 per microliter
  • Known bleeding disorders or recent anticoagulant therapy with high INR
  • Severe high blood pressure (systolic >220 mmHg or diastolic >120 mmHg)
  • Suspected septic embolus or bacterial endocarditis
  • Previous endovascular treatment attempted for current stroke
  • Unlikely to participate in follow-up assessments
  • Currently enrolled in another clinical trial affecting outcomes
  • Other conditions posing significant risk as judged by the investigator
  • Presence of intracranial hemorrhage or brain tumor (except small meningioma)
  • Significant brain swelling with midline shift
  • Aortic dissection
  • Intracranial stent in the same vascular territory
  • Vascular anatomy preventing safe or effective endovascular treatment
  • Multiple vessel occlusions confirmed on imaging (e.g., bilateral MCA occlusions)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Changhai Hospital

Shanghai, China

Actively Recruiting

Loading map...

Research Team

L

Lily Song, PhD

CONTACT

C

Craig Anderson, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here